← Sazabi Research

BeOne Medicines (ONC)

China's Biotech Champion Goes Global — H1 Profit Surges 627%, BRUKINSA Franchise Hits $4.5B Run-Rate — Quick Take

📅 August 10, 2026 HealthcareBiotechChina ADROncology
Market Cap
~$36B
Revenue (TTM)
$6.13B
P/E (Fwd)
44x
Rev Growth
+34%

Why This Company Now

The daily financial summary flagged a major structural theme: global pharmaceutical giants are increasingly turning to Chinese biotech firms to tap innovation pipelines, with cross-border out-licensing by Chinese biotechs hitting $60 billion in Q1 2026 alone — a 73% jump YoY. BeOne Medicines (formerly BeiGene) is the poster child of this convergence. It appeared directly in the US VolumeSurge screener on Friday (+5.6%, $348.27, $222M turnover), Healthcare was the #4 sector in today's HK VolumeSurge (6 stocks), and the company just dropped a blowout H1 2026 report: net profit surged 627% to $485M, already exceeding full-year 2025 profit. BRUKINSA global sales hit a $4.5B annual run-rate, and the FDA just granted accelerated approval to Sonrotoclax (BEQALZI) for relapsed/refractory mantle cell lymphoma. Multiple analysts raised price targets following the print — TD Cowen to $454, Morgan Stanley to $405.

Financial Snapshot

YearRevenueRev GrowthOp MarginNet Income
2022$1.42B+20.4%-126.4%-$2.00B
2023$2.46B+73.7%-49.1%-$0.88B
2024$3.81B+55.0%-14.9%-$0.64B
2025$5.34B+40.2%+8.4%$0.29B
TTM (Jun '26)$6.13B+34.4%+15.1%$0.66B

2026 guidance raised to $6.7–6.8B (44.9–46.2B yuan). BRUKINSA accounts for ~74% of total revenue ($4.5B TTM). Gross margin expanded to 88.9% TTM. Free cash flow flipped positive in 2025 ($942M) and hit $1.33B TTM.

Bull vs Bear

✅ Bull Case

  • BRUKINSA is a global blockbuster franchise — $4.5B annual run-rate growing 28%+ YoY, #1 BTK inhibitor by new patient share in the U.S. MANGROVE trial (chemo-free frontline MCL) just read out positive with HR 0.57; global regulatory filings planned H2 2026 could extend the franchise further.
  • Operating leverage has arrived — Op margin swung from -126% (2022) to +15% TTM. Free cash flow flipped from -$1.8B to +$1.33B in three years. H1 2026 net profit of $485M already exceeds all of FY2025. This is the inflection everyone waited for.
  • Pipeline depth de-risks the story — Sonrotoclax just won accelerated FDA approval (Aug 5); TEVIMBRA (PD-1) growing in EU; 40+ clinical/commercial stage assets; potential accelerated approval for tacabrutinib+sonrotoclax in R/R CLL by YE 2026; phase III starts for GPC3-4-1BB and B7-H4 ADC. China BD deal boom ($60B Q1) affirms the platform thesis.

🔴 Bear Case

  • BRUKINSA concentration is extreme — 74% of revenue depends on a single molecule. If competitive pressure intensifies from AbbVie/J&J (ibrutinib/Imbruvica), AstraZeneca (acalabrutinib/Calquence), or Merck's nemtabrutinib, the entire earnings thesis cracks. BTK inhibitors are a crowded class.
  • CELESTIAL-301 trial miss raises pipeline execution risk — The zanubrutinib + sonrotoclax combo failed to beat venetoclax + obinutuzumab in first-line CLL. This was supposed to be the follow-on franchise. Questions remain about whether BeOne can replicate BRUKINSA's success organically.
  • Valuation already prices in perfection — 44x forward P/E, 6.5x trailing P/S. The redomiciliation to Switzerland and rebranding to BeOne adds shareholder complexity (triple-listed: NASDAQ/HKEX/Shanghai STAR). Any stumble in BRUKINSA growth trajectory and the multiple compresses fast — this was a -$2B net loss company just three years ago.

Verdict

BeOne Medicines is the best pure-play on the China biotech globalization thesis — and the numbers are finally catching up to the narrative. The operating leverage inflection is real: a company that burned $2B in 2022 is now printing $1.3B in free cash flow. BRUKINSA is a genuine global blockbuster, and the Sonrotoclax approval opens a second front. But at 44x forward earnings with 74% single-product concentration, the margin for error is thin. If you believe the China biotech BD boom is structural and BRUKINSA still has a multi-year growth runway, the post-earnings pullback from A-share highs could be an entry point. If you worry about BTK competition or pipeline execution, wait for a better price. Either way, this is the Chinese biotech name to watch in H2 2026.

Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings, company reports, and financial data providers. BeOne Medicines trades as ONC (NASDAQ), 06160.HK (HKEX), and 688235.SS (Shanghai STAR).